ARKG vs. BIB
ARKG (ARK Genomic Revolution Multi-Sector ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) are both exchange-traded funds - ARKG is a Health & Biotech Equities fund actively managed by ARK, while BIB is a Leveraged Equities fund tracking the NASDAQ Biotechnology Index (200%). ARKG is actively managed, while BIB is passively managed. Over the past 10 years, ARKG returned 8.67%/yr vs 9.71%/yr for BIB. A 0.77 correlation means they provide meaningful diversification when combined. ARKG charges 0.75%/yr vs 0.95%/yr for BIB.
Performance
ARKG vs. BIB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ARKG achieves a 24.30% return, which is significantly higher than BIB's 12.50% return. Over the past 10 years, ARKG has underperformed BIB with an annualized return of 8.67%, while BIB has yielded a comparatively higher 9.71% annualized return.
ARKG
- 1D
- -1.07%
- 1M
- 17.41%
- YTD
- 24.30%
- 6M
- 19.48%
- 1Y
- 52.71%
- 3Y*
- 3.17%
- 5Y*
- -16.56%
- 10Y*
- 8.67%
BIB
- 1D
- 1.97%
- 1M
- 9.49%
- YTD
- 12.50%
- 6M
- 8.62%
- 1Y
- 100.86%
- 3Y*
- 19.65%
- 5Y*
- -0.74%
- 10Y*
- 9.71%
ARKG vs. BIB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ARKG ARK Genomic Revolution Multi-Sector ETF | 24.30% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 44.00% | -1.26% | 46.61% |
BIB ProShares Ultra Nasdaq Biotechnology | 12.50% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
Correlation
The correlation between ARKG and BIB is 0.67, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.67 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.73 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.78 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.79 |
Correlation (All Time) Calculated using the full available price history since Oct 31, 2014 | 0.77 |
The correlation between ARKG and BIB shifts across timeframes, from 0.67 (1 year) to 0.79 (10 years), reflecting how their relationship changes across market environments.
ARKG vs. BIB - Sectors Allocation Comparison
Sectors
ARKG
BIB
Healthcare
Financial Services
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
ARKG
BIB
Financial Services
ARKG
BIB
Basic Materials
ARKG
-
BIB
-
Communication Services
ARKG
-
BIB
-
Consumer Cyclical
ARKG
-
BIB
-
Consumer Defensive
ARKG
-
BIB
-
Energy
ARKG
-
BIB
-
Industrials
ARKG
-
BIB
-
Real Estate
ARKG
-
BIB
-
Technology
ARKG
-
BIB
-
Utilities
ARKG
-
BIB
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ARKG vs. BIB — Risk / Return Rank
ARKG
BIB
ARKG vs. BIB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ARK Genomic Revolution Multi-Sector ETF (ARKG) and ProShares Ultra Nasdaq Biotechnology (BIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARKG | BIB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.26 | ||
| Sortino ratioReturn per unit of downside risk | -1.16 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.36 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 1.93 | 5.99 | -4.07 |
| Martin ratioReturn relative to average drawdown | 4.58 | 18.30 | -13.72 |
Loading charts...
Drawdowns
ARKG vs. BIB - Drawdown Comparison
The maximum ARKG drawdown since its inception was -83.59%, which is greater than BIB's maximum drawdown of -67.24%. Use the drawdown chart below to compare losses from any high point for ARKG and BIB.
Loading charts...
Drawdown Indicators
| ARKG | BIB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.59% | -67.24% | -16.35% |
Max Drawdown (1Y)Largest decline over 1 year | -27.51% | -16.92% | -10.59% |
Max Drawdown (3Y)Largest decline over 3 years | -51.96% | -45.30% | -6.66% |
Max Drawdown (5Y)Largest decline over 5 years | -80.18% | -65.86% | -14.32% |
Max Drawdown (10Y)Largest decline over 10 years | -83.59% | -66.20% | -17.39% |
Current DrawdownCurrent decline from peak | -67.78% | -17.29% | -50.49% |
Average DrawdownAverage peak-to-trough decline | -36.02% | -32.71% | -3.31% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.53% | 5.53% | +6.00% |
Volatility
ARKG vs. BIB - Volatility Comparison
ARK Genomic Revolution Multi-Sector ETF (ARKG) has a higher volatility of 15.19% compared to ProShares Ultra Nasdaq Biotechnology (BIB) at 13.56%. This indicates that ARKG's price experiences larger fluctuations and is considered to be riskier than BIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ARKG | BIB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.19% | 13.56% | +1.63% |
Volatility (6M)Calculated over the trailing 6-month period | 30.91% | 31.65% | -0.74% |
Volatility (1Y)Calculated over the trailing 1-year period | 42.54% | 40.43% | +2.11% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 45.93% | 43.60% | +2.33% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 41.29% | 46.39% | -5.10% |
ARKG vs. BIB - Expense Ratio Comparison
ARKG has a 0.75% expense ratio, which is lower than BIB's 0.95% expense ratio.
Dividends
ARKG vs. BIB - Dividend Comparison
ARKG has not paid dividends to shareholders, while BIB's dividend yield for the trailing twelve months is around 0.55%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% |
BIB ProShares Ultra Nasdaq Biotechnology | 0.55% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
ARKG and BIB have a correlation of 0.67, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ARKG has higher volatility (15.19%) compared to BIB (13.56%). In terms of maximum drawdown, ARKG dropped -83.59% vs BIB's -67.24%.
On 10-year performance, BIB leads with 9.71% vs 8.67% for ARKG. On fees, ARKG is cheaper at 0.75% per year. On volatility, BIB has been the lower-risk option at 13.56%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, BIB has performed better with a 9.71% return vs 8.67%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
ARKG is cheaper with a 0.75% expense ratio, compared with 0.95% for BIB.
BIB has the higher dividend yield at 0.55%, compared with 0.00% for ARKG.
ARKG is categorized as Health & Biotech Equities, while BIB is Leveraged Equities. They also come from different issuers: ARK and ProShares. Their fees differ too: 0.75% for ARKG and 0.95% for BIB.
BIB currently has the higher Sharpe Ratio (2.51 vs 1.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ARKG and BIB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer